- Home
- RIGL vs MTLS Comparison
RIGL vs MTLS Comparison
Compare RIGL & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- MTLS
- Stock Information
- Founded
- RIGL 1996
- MTLS 1990
- Country
- RIGL United States
- MTLS Belgium
- Employees
- RIGL N/A
- MTLS N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- MTLS Computer Software: Prepackaged Software
- Sector
- RIGL Health Care
- MTLS Technology
- Exchange
- RIGL Nasdaq
- MTLS Nasdaq
- Market Cap
- RIGL 335.5M
- MTLS 349.7M
- IPO Year
- RIGL 2000
- MTLS 2014
- Fundamental
- Price
- RIGL $21.91
- MTLS $5.02
- Analyst Decision
- RIGL Buy
- MTLS
- Analyst Count
- RIGL 5
- MTLS 0
- Target Price
- RIGL $36.40
- MTLS N/A
- AVG Volume (30 Days)
- RIGL 182.1K
- MTLS 114.8K
- Earning Date
- RIGL 08-05-2025
- MTLS 07-24-2025
- Dividend Yield
- RIGL N/A
- MTLS N/A
- EPS Growth
- RIGL N/A
- MTLS N/A
- EPS
- RIGL 2.08
- MTLS 0.11
- Revenue
- RIGL $203,077,000.00
- MTLS $311,850,851.00
- Revenue This Year
- RIGL $14.41
- MTLS $5.28
- Revenue Next Year
- RIGL $15.97
- MTLS $7.82
- P/E Ratio
- RIGL $10.11
- MTLS $48.78
- Revenue Growth
- RIGL 70.16
- MTLS 2.98
- 52 Week Low
- RIGL $8.61
- MTLS $3.93
- 52 Week High
- RIGL $29.82
- MTLS $9.69
- Technical
- Relative Strength Index (RSI)
- RIGL 66.30
- MTLS 34.00
- Support Level
- RIGL $19.51
- MTLS $5.14
- Resistance Level
- RIGL $21.41
- MTLS $5.57
- Average True Range (ATR)
- RIGL 0.88
- MTLS 0.24
- MACD
- RIGL 0.24
- MTLS -0.10
- Stochastic Oscillator
- RIGL 96.45
- MTLS 7.87
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.